Aptose Biosciences Announces Q4 And FY 2022 Results
By Amit Chowdhry ● Mar 24, 2023
Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.